Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386660787> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4386660787 abstract "Abstract Background/Introduction Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) levels and the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) in clinical trials. In January 2019, evolocumab reimbursement recommendation in Sweden was broadened to include patients on maximally tolerated oral lipid-lowering therapy (LLT) and either ASCVD and LDL-C ≥2.5 mmol/L, or familial hypercholesterolemia (FH) with no ASCVD and LDL-C ≥3.0 mmol/L. Purpose Describe characteristics and LLT use in patients initiating treatment with evolocumab in the context of the 2019 reimbursement recommendation in Sweden. Methods Cross-sectional, population-based, retrospective, observational study of patients initiating treatment with evolocumab between January 2019 and June 2020. Data were obtained from national healthcare registers and electronic medical records, covering more than half of the Swedish population. Results Out of 1560 patients included, 41% had LDL-C available ≤3 months prior to treatment initiation with evolocumab. Among those with LDL-C available, 79% had ASCVD and 19% had definite, probable or possible FH with no ASCVD. Mean pre-treatment LDL-C levels were 3.7 and 5.0 mmol/L for patients with ASCVD, and FH with no ASCVD, respectively. Most of the patients, 84.6% and 80.0%, respectively, had been ever treated with both statins and ezetimibe. However, 28.0% and 38.3% of them, respectively, were not on oral LLT at the time of treatment initiation with evolocumab. Patient characteristics and LLT use are presented in Table 1. Conclusions Patients initiating treatment with evolocumab in Sweden had pre-treatment LDL-C levels far from treatment targets, despite being at very high risk for cardiovascular events. Most of the patients had been treated with both statins and ezetimibe in the past. However, almost a third of them were not using oral LLT at the time of treatment initiation with evolocumab. The conditions in the 2019 evolocumab reimbursement recommendation in Sweden were generally met. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Amgen" @default.
- W4386660787 created "2023-09-13" @default.
- W4386660787 creator A5002227117 @default.
- W4386660787 creator A5004259321 @default.
- W4386660787 creator A5027035779 @default.
- W4386660787 creator A5031997572 @default.
- W4386660787 creator A5042288449 @default.
- W4386660787 creator A5044376308 @default.
- W4386660787 creator A5044939013 @default.
- W4386660787 creator A5050951058 @default.
- W4386660787 creator A5073596004 @default.
- W4386660787 date "2021-10-01" @default.
- W4386660787 modified "2023-10-18" @default.
- W4386660787 title "A real-world analysis of characteristics and lipid-lowering therapy use in patients initiating treatment with evolocumab in Sweden" @default.
- W4386660787 doi "https://doi.org/10.1093/eurheartj/ehab724.2590" @default.
- W4386660787 hasPublicationYear "2021" @default.
- W4386660787 type Work @default.
- W4386660787 citedByCount "0" @default.
- W4386660787 crossrefType "journal-article" @default.
- W4386660787 hasAuthorship W4386660787A5002227117 @default.
- W4386660787 hasAuthorship W4386660787A5004259321 @default.
- W4386660787 hasAuthorship W4386660787A5027035779 @default.
- W4386660787 hasAuthorship W4386660787A5031997572 @default.
- W4386660787 hasAuthorship W4386660787A5042288449 @default.
- W4386660787 hasAuthorship W4386660787A5044376308 @default.
- W4386660787 hasAuthorship W4386660787A5044939013 @default.
- W4386660787 hasAuthorship W4386660787A5050951058 @default.
- W4386660787 hasAuthorship W4386660787A5073596004 @default.
- W4386660787 hasBestOaLocation W43866607871 @default.
- W4386660787 hasConcept C126322002 @default.
- W4386660787 hasConcept C151730666 @default.
- W4386660787 hasConcept C2776839432 @default.
- W4386660787 hasConcept C2778114629 @default.
- W4386660787 hasConcept C2778163477 @default.
- W4386660787 hasConcept C2778657065 @default.
- W4386660787 hasConcept C2778715236 @default.
- W4386660787 hasConcept C2779134260 @default.
- W4386660787 hasConcept C2779343474 @default.
- W4386660787 hasConcept C2780072125 @default.
- W4386660787 hasConcept C2780745583 @default.
- W4386660787 hasConcept C2780902209 @default.
- W4386660787 hasConcept C2780948078 @default.
- W4386660787 hasConcept C2908647359 @default.
- W4386660787 hasConcept C2909478654 @default.
- W4386660787 hasConcept C43554185 @default.
- W4386660787 hasConcept C62746215 @default.
- W4386660787 hasConcept C71924100 @default.
- W4386660787 hasConcept C86803240 @default.
- W4386660787 hasConcept C99454951 @default.
- W4386660787 hasConceptScore W4386660787C126322002 @default.
- W4386660787 hasConceptScore W4386660787C151730666 @default.
- W4386660787 hasConceptScore W4386660787C2776839432 @default.
- W4386660787 hasConceptScore W4386660787C2778114629 @default.
- W4386660787 hasConceptScore W4386660787C2778163477 @default.
- W4386660787 hasConceptScore W4386660787C2778657065 @default.
- W4386660787 hasConceptScore W4386660787C2778715236 @default.
- W4386660787 hasConceptScore W4386660787C2779134260 @default.
- W4386660787 hasConceptScore W4386660787C2779343474 @default.
- W4386660787 hasConceptScore W4386660787C2780072125 @default.
- W4386660787 hasConceptScore W4386660787C2780745583 @default.
- W4386660787 hasConceptScore W4386660787C2780902209 @default.
- W4386660787 hasConceptScore W4386660787C2780948078 @default.
- W4386660787 hasConceptScore W4386660787C2908647359 @default.
- W4386660787 hasConceptScore W4386660787C2909478654 @default.
- W4386660787 hasConceptScore W4386660787C43554185 @default.
- W4386660787 hasConceptScore W4386660787C62746215 @default.
- W4386660787 hasConceptScore W4386660787C71924100 @default.
- W4386660787 hasConceptScore W4386660787C86803240 @default.
- W4386660787 hasConceptScore W4386660787C99454951 @default.
- W4386660787 hasIssue "Supplement_1" @default.
- W4386660787 hasLocation W43866607871 @default.
- W4386660787 hasOpenAccess W4386660787 @default.
- W4386660787 hasPrimaryLocation W43866607871 @default.
- W4386660787 hasRelatedWork W2626674165 @default.
- W4386660787 hasRelatedWork W2751210700 @default.
- W4386660787 hasRelatedWork W2751694839 @default.
- W4386660787 hasRelatedWork W2790280068 @default.
- W4386660787 hasRelatedWork W2911702236 @default.
- W4386660787 hasRelatedWork W2922111129 @default.
- W4386660787 hasRelatedWork W2932844247 @default.
- W4386660787 hasRelatedWork W2979834087 @default.
- W4386660787 hasRelatedWork W4366606415 @default.
- W4386660787 hasRelatedWork W2169633553 @default.
- W4386660787 hasVolume "42" @default.
- W4386660787 isParatext "false" @default.
- W4386660787 isRetracted "false" @default.
- W4386660787 workType "article" @default.